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Astrocytes: Initiators of and 
Responders to Inflammation
Allison Soung and Robyn S. Klein
Abstract
We are in the midst of a glial renaissance; astrocytes, essential for brain 
homeostasis and neuroprotection, have experienced resurgence in focused 
analyses. New roles in synaptic plasticity, innate immunity and control of 
recruited immune cells have placed astrocytes at the center of central nervous 
system functions. Astrocytes have been shown to receive and convey information 
to all neural cell types in a coordinated effort to respond to injury and infection, 
initiating reparative mechanisms. Astrocytes detect injury and infection signals 
from neurons, microglia, oligodendrocytes and endothelial cells, responding 
by secreting cytokines, chemokines and growth factors, which may activate 
immune defenses. While regional heterogeneity in astrocyte form and function 
has been appreciated since the early 1990s, technologic advances have allowed 
scientists to show only that astrocytes may be as individualized as neurons. Adult 
astrocytes may undergo a morphological and functional transformation referred 
to as astrogliosis. Newly generated astrocytes exhibit heterogenous phenotypes; 
thus, some remove toxic molecules, restore blood-brain barrier function, and 
promote extracellular matrix components to support axonal growth and repair, 
while others inhibit neuronal repair and regeneration. This chapter will introduce 
some of the cellular and molecular components involved in astrocyte responses 
induced by inflammatory mediators or pathogens during neuroinflammation or 
neuroinfectious diseases.
Keywords: astrocyte, cytokines, chemokines, pathogens, viruses, bacteria, 
astrogliosis
1. Introduction
Astrocytes are a principle participant in central nervous system (CNS) responses 
to neurological disorders or diseases [1–3]. During development and homeostasis, 
astrocytes coordinate immune responses by regulating microglia activation and 
blood-brain barrier (BBB) formation [4, 5]. Through dedicated molecular cascades, 
astrocytes also provide growth factors to neurons, support synapse formation, 
and help regulate extracellular balance of ions and neurotransmitters, making 
these glial cells essential for brain homeostasis [6, 7]. In response to CNS injury 
and disease, astrocytes undergo a process termed astrogliosis, a multifactorial 
and complex remodeling of astrocytes [7–10]. Despite the use of a single term to 
describe astrocyte reaction to insult, astrogliosis results in a spectrum of heterog-
enous changes in a context specific manner that vary with etiology and severity of 
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CNS injury [9–13]. Classically, this process is characterized by upregulation of glial 
fibrillary acid protein (GFAP) and vimentin, key astrocyte intermediate filaments, 
and hypertrophy of astrocyte processes [14] (Figure 1). Changes in astrocyte 
biochemistry and physiology that may result in the secretion of anti-inflammatory 
and pro-inflammatory factors also contribute to this process [10, 15–17].
2. Astrogliosis
Functionally, astrogliosis results in the expression of molecules that provide 
neurotrophic support to injured neurons, isolate damaged area and CNS inflam-
mation from healthy CNS tissue, rebuild and maintain a compromised BBB, 
and contribute circuitry remodeling around the lesioned region [7, 9–12, 18]. 
Consistent with this, studies using animal models of traumatic brain injury, 
spinal cord injury, and autoimmunity, all reveal that the loss of reactive astro-
cytes during acute processes leads to the exacerbation of clinical symptoms, 
recruit of immune molecules, changes in BBB integrity, and neuronal death 
[7, 10, 19]. The overall goals of these functional reactions are therefore beneficial 
for the CNS. However, past research has also highlighted detrimental and inhibi-
tory effects of astrogliosis, including augmentation of inflammation, as well as 
inhibition of neuronal repair and axonal growth [20, 21]. The dual outcomes 
of astrogliosis highlight the time- and context-specific way this process may be 
regulated. Future studies of this process may ultimately determine mechanisms 
to manipulate astrogliosis as a therapeutic target to improve CNS injury outcomes 
[10, 22].
Astrogliosis is induced and regulated by a variety of extracellular molecules, 
such as neurotransmitters, steroid hormones, cytokines and neurodegeneration-
associated molecules (Table 1). Intracellular signaling pathways, such cyclic AMP 
(cAMP), signal transducer and activator of transcription 3 (STAT3), nuclear factor 
kappa B (NFκB), Rho-kinase, and calcium have all been observed to induce the 
expression of GFAP or vimentin [11, 45–47]. Extracellular signaling pathways, 
including responses to epidermal growth factor (EGF), fibroblast growth factor 
Figure 1. 
Astrogliosis is typically characterized by hypertrophy of astrocyte processes. Expression of GFAP+ astrocytes 
(green) and DAPI (blue) in a mock-infected mouse CA3 hippocampus (A) and in a West Nile virus-infected 
CA3 hippocampus 7 days post infection (B). Viral infection triggers reactive astrogliosis in the hippocampus, in 
which the processes of activated astrocytes show hypertrophy.
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Signaling 
pathway
Injury Chemokines/cytokines 
released
Immune/functional 
outcome
References
ERα signaling EAE Reduction of 
leukocyte molecules
[23]
Gp103/IL-6 
signaling
EAE Downregulation of IL-17 
and IFNγ
Reduction of T 
cell infiltration, 
inhibition of 
astrocyte apoptosis, 
improvement of 
disease course
[24, 25]
Infection Downregulation of IFNγ Inhibition of 
astrocyte apoptosis, 
decrease of pathogen 
burden
[25]
IL-1β signaling Traumatic 
injury, 
infection
Increase of GFAP 
expression
[26, 27]
IL-17 signaling EAE Upregulation of CXCL2 Increase of leukocyte 
infiltration, worsen 
disease course
[28]
IFNγ signaling EAE Downregulation of 
CCL5, IL-1β and TNF
Improved course of 
disease
[24]
Traumatic 
injury
Increase of GFAP 
expression
[29]
TNFR1 
signaling
EAE Increases of T cell 
infiltration, worsen 
disease course
[30]
NFκB signaling EAE Upregulation of 
CCL2, CCL5, CXCL10, 
IL-1β, IFNγ, and TNF; 
downregulation of IL-6
Reduction of 
leukocyte molecules, 
increase in axon 
pathology, worsen 
disease course
[31]
Ischemia, 
traumatic 
injury
Upregulation of CCL2, 
CCL5, CXCL10, IL-6, 
TGF-β and TNF
Increase of 
leukocytes 
molecules, reduction 
of GFAP expression, 
increase of neuronal 
damage
[31–33]
Notch signaling Ischemia Reduction of 
leukocyte molecules, 
increase of GFAP 
expression, increase 
of astrocyte 
proliferation
[34, 35]
SHH signaling EAE Maintenance of BBB [36]
Soc3 signaling Traumatic 
injury
Increase of leukocyte 
molecules, increase 
of GFAP expression
[37]
STAT3 signaling Traumatic 
injury
Reduction of 
leukocyte molecules, 
inhibition of GFAP 
expression
[37, 38]
Traumatic 
injury
Increase of GFAP and 
vimentin expression
[39, 40]
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(FGF), sonic hedgehog (SHH), and albumin, can also regulate astrocyte prolifera-
tion [9, 48–50]. Specific pro- and anti-inflammatory effects of reactive astrocytes 
may be regulated separately. Thus, the genetic ablation of STAT3 within astrocytes, 
or its associated membrane receptor gp130, leads to increased inflammation 
during autoimmune disease, traumatic injury and infection [24, 37–39, 51], while 
genetic deletion of NFκB or the suppressor of cytokine signaling 3 (Soc3) signal-
ing pathway in astrocytes decreases the recruitment of immune cells [31, 32, 37]. 
Furthermore, recruited immune cells release numerous cytokines that may further 
stimulate astrocyte activation (Table 1). In addition, recent studies indicate that 
microglia critically induce astrogliosis via expression of pro-inflammatory cyto-
kines, including interleukin (IL)-1β, tumor necrosis factor (TNF), and interferon 
(IFN)-γ [26, 52, 53].
In response to injury, reactive astrocytes were previously believed to migrate 
to the lesion site. Recent live imaging studies, however, indicate that astrocytes do 
not migrate towards the lesion site [54]. Instead, astrocytes remain in their tiled-
domains and become hypertrophic [54, 55]. Neither proliferation nor migration of 
astrocytes contribute to the total increase of GFAP positive cells observed at lesion 
sites. This has led to a new focus on identifying other sources for adult astrocytes. 
Currently, there is evidence that radial glia, neuronal progenitor cells (NPCs) 
within the subventricular (SVZ) and subgranular (SGZ) zones, locally proliferating 
glia, in addition to NG2+ cells may all contribute to newly generated pools of reac-
tive astrocytes after injury [56].
3. Astrocytes as the gatekeeper to the CNS
During homeostasis, astrocyte end-feet enwrap the brain microvascular endo-
thelial cells, helping maintain the integrity of the BBB. Their physical interaction 
with the BBB allows astrocytes to influence the entry of peripheral immune cells 
into the CNS during injury or disease as well as modulating their activity once 
entering the CNS parenchyma. In health, astrocytes, along with multiple other cell 
types, support the BBB as well as express localizing cues that restrict leukocytes 
Signaling 
pathway
Injury Chemokines/cytokines 
released
Immune/functional 
outcome
References
TGF-β signaling Traumatic 
injury
Increase of leukocyte 
molecules, increase 
of GFAP expression, 
increase of ECM 
components
[41–43]
Infection Inhibition of 
NFκB signaling; 
downregulation of CCL5
Reduction of T cell 
infiltration, decrease 
of neuronal death
[44]
A variety of intracellular signaling molecules have been shown to induce reactive astrogliosis or to modulate aspects 
of the reactive astrogliosis process. In response to a range of CNS injuries, all cell types within the CNS, such as 
neurons, microglia, other astrocytes, endothelium, and pericytes, can release signaling molecules that are able to 
trigger astrogliosis.
BBB = blood-brain barrier, CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, 
ER = estrogen receptor, Gp = glycoprotein, IL = interleukin, IFN = interferon, NFκB = nuclear factor kappa 
B, EAE = experimental autoimmune encephalomyelitis, ECM = extracellular matrix, SHH = sonic hedgehog, 
Soc3 = suppressor of cytokine signaling 3, STAT3 = signaling transducer and activator of transcription 3, 
TGF = transforming growth factor β, TNF = tumor necrosis factor.
Table 1. 
Triggers of reactive astrogliosis.
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access into the CNS parenchyma [17, 57–59]. However, CNS damage caused by 
stroke, traumatic injury, infection, autoimmune disease, and neurodegenerative 
disorders leads to the disruption of the BBB, which may increase the CNS entry of 
immune cells [24, 25, 38, 39, 60–66].
During injury or infection, astrocytes detect molecular changes in their 
extracellular environment and in neighboring cells. In stroke, astrocytes become 
reactive when oxygen and glucose deprivation occurs [67, 68]. In most neurologi-
cal disorders, the release of neurotransmitters and adenosine triphosphate (ATP) 
from damaged neurons is detected by astrocytes via P2X and P2Y purinergic 
receptors [69, 70]. During viral infections, toll-like receptors (TLRs), such as 
TLR3, 7, and 9, and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), 
are expressed on neurons, astrocytes, and microglia. These receptors are examples 
of pattern recognition receptors (PPRs) that are differentially activated by patho-
gen-associated molecular patterns (PAMPs) derived from invading bacteria, fungi, 
or viruses [71]. Activation of TLRs and RLRs by PAMPs or damage-associated 
molecular patterns (DAMPs) have been shown to contribute to neuronal damage, 
induce microglia and astrocyte activation and production of cytokines, including 
type I IFNs [72–74]. Type I IFNs, along with numerous other innate cytokines, 
such as IL-6, IL-1β, IFN-γ, and TNF, have been shown to regulate BBB integrity 
through a variety of different mechanisms that include the regulation of Rho 
GTPases, activation of matrix metallopeptidase 9 (MMP9), and suppression of 
other pro-inflammatory cytokines, including IL-1β, IL-6, and TNF [75, 76]. In 
support of this, the genetic astrocyte-specific deletion of the type I IFN receptor, 
IFNαβR (IFNAR), results in enhanced BBB permeability in a murine viral infec-
tion model [77].
The entry of leukocytes into the CNS parenchyma involves their passage across 
the BBB, whose permeability is regulated by astrocytes and pericytes, as well as 
multiple other cell types [57–59]. Once leukocytes traverse the BBB, they local-
ize within perivascular spaces and where they interact with numerous cell types, 
including astrocytes [78]. Astrocytes, thus, take part in both the recruitment and 
restriction of leukocytes in the CNS [58, 59, 151]. Their functions, however, occur 
in a context-specific manner via specific signaling events. It is remarkable how 
astrocytes are able to respond to a diverse number of signaling mechanisms in the 
orchestration BBB disruption, the recruitment of leukocytes, and the amplifica-
tion of their pro-inflammatory effects [17, 57, 79, 80], while also being capable of 
contributing to BBB repair, restricting leukocyte trafficking, and exerting anti-
inflammatory effects that promote the resolution of inflammation [6, 9–11].
4. Reactive astrocytes as a physical barrier
At the site of injury, newly proliferated astrocytes form scars, in which 
bundles of reactive astrocytes polarize with extracellular matrix (ECM) compo-
nents and physically surround the lesioned site [38]. The earliest studies focused 
on the formation of the astrocyte scar and its importance in repairing the BBB 
after traumatic brain injury [61, 62]. Astrocyte scars form a physical, functional 
barrier that restricts the entry of leukocytes after traumatic brain injuries, 
ischemia, neurodegeneration and autoimmune inflammation [37, 38]. This is 
achieved through the upregulation of ECM proteins, such as fibronectin and 
laminin, as well as chondroitin sulfate proteoglycans (CSPGs) [41, 42, 81–84]. 
Structural proteins, such as GFAP and vimentin, have also been shown to be 
important for the formation of the astrocyte scar [14]. Mice with global genetic 
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deletion of these molecules display increased inflammation and pathology as 
well as worsened functional outcomes in various CNS injury models, such as 
ischemia, traumatic injury, autoimmune inflammation, infection, and neurode-
generation [11, 63, 64, 85–88].
The astrocyte scar is also important for localizing immune cells and limiting the 
invasion of infectious pathogens, to the lesion site. For example, the genetic dele-
tion of GFAP+ cells leads to increases in immune cell infiltrations in murine models 
of traumatic injury and autoimmunity [60, 61]. Genetic loss of GFAP expression 
also increases pathogen burden in various infections, including Staphylococcus 
aureus and Toxoplasma gondii [89]. Multiple studies have shown that the restriction 
of leukocyte entry and migration after infection, autoimmune inflammation, and 
traumatic brain injury is mediated by astrocyte anti-inflammatory functions via 
the JAK2-STAT3 signaling pathway in GFAP+ cells [25, 38, 39]. The genetic deletion 
of astrocyte derived STAT3 signaling prevents scar formation and limits immune 
cell infiltration in a spinal cord injury model [39]. These observations suggest that 
the astrocyte scar serves as a functional barrier to restrict cytotoxic inflammatory 
molecules and cells.
Studies genetically deleting essential components of the ECM, such as MMP9, or 
inhibiting signaling pathways, including Rho/ROCK, to block CSPG activity have 
shown astrogliosis to exacerbate inflammation after traumatic injury or autoim-
mune inflammation as well as preventing axonal growth and behavioral recovery 
[81, 90–92]. The astrocyte scar has also been shown to exhibit a diverse array of 
molecules known to prevent axonal growth, such as CSPGs, semaphoring 3A, 
keratan sulfate proteoglycans (KSPGs) and ephrins/Eph receptors [19, 93, 94]. The 
complexity of astrocytes in producing, recruiting and restricting inflammatory cells 
and other molecules have made these cells a difficult target for potential therapeutic 
manipulation.
5. Astrocytes as a regulator of the innate immune response
After CNS injury or infection, reactive astrocytes release molecules that attract, 
recruit and facilitate the migration of immune cells to the lesion site (Figure 2). 
Astrocytes express leukocyte adhesion molecules, including vascular cell adhesion 
and intercellular adhesion molecules, in models of ischemia, autoimmunity, and 
infection [30, 33, 95]. Specifically, in an ischemia model, astrocytes release NF-κB, 
which increases both vascular cell adhesion and intercellular adhesion molecules 
[33, 96]. These adhesion molecules promote intercellular interactions that contrib-
ute to the trafficking of immune cells to the lesion site.
Like microglia, the resident macrophages of the CNS, astrocytes play a role in 
innate immune responses by producing cytokines and chemokines, such as type 
I and II IFNs and TNF, that promote the expression of hundreds of interferon-
stimulated genes (ISGs), such as those that participate in inflammatory cell infil-
tration [97, 98]. Microglia also upregulate the expression of numerous receptors 
and produce various chemokines after CNS injury, such as chemokine (C-X3-C 
motif) receptor 1 (CX3CR1) and chemokine (C-C motif) receptor 2 (CCR2) [99]. 
Similarly, reactive astrocytes also express many of these receptors and chemokines, 
suggesting that astrocytes and microglia communicate via chemokines. In fact, 
astrocyte release of chemokines has been shown to be important for attracting 
peripheral and CNS myeloid cells to the lesion site. In models of traumatic injury 
and parasitic infection, astrocytes are a source of chemokine (C-C motif) ligand 
2 (CCL2) [100, 101]. Astrocytes have also been shown to produce chemokine 
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(C-X3-C motif) ligand 1 (CXC3L1) and CXCL1, detected by monocytes and 
microglia, in response to viral infection and spinal cord injury, respectively 
[102–104].
After entry into the brain, or activation within the brain, innate immune cells 
demonstrate a spectrum of phenotypes, ranging from pro- and anti-inflammatory 
states, and can express a variety of cytokines and chemokines, including IL-1β, 
IFN-γ, and TNF, that contribute to neuroinflammation [105]. Reactive astrocytes 
have a demonstrated role in modulating immune responses by releasing cytokines 
that stimulate microglia and macrophages to adopt either pro- or anti-inflammatory 
responses. For example, after injury or infection, astrocytes have been shown to 
release cytokines, such as IFN-γ, TNF, and IL-12, that shift microglia and macro-
phages to a more pro-inflammatory phenotype [106, 107]. Under similar conditions, 
however, astrocytes have also been observed to produced cytokines, including IL-10 
and transforming growth factor beta (TGF-β), which can shift monocytes towards a 
less inflammatory states [108–110]. These findings support the notion that astrocyte 
responses may be context dependent.
6. Astrocytes as a regulator of the adaptive immune response
During the adaptive immune response, astrocytes are a major source of T and 
B cells chemoattractants. Reactive astrocytes express CCL5 as well as CXCL10 in 
infection models, both chemoattractants of T cells [111–113]. In viral infection 
models, CXCL10 has been shown to be an important ligand for CXCR3 on CD8+ T 
cells [114]. The recruitment of such CXCR3+ T cells results in improved viral con-
trol and survival after infection [115]. In brain samples from patients with multiple 
Figure 2. 
Reactive astrocytes regulate immune responses. Activation of astrocytes, either directly by purinergic 
receptors or PRRs or indirectly, promote expression of inflammatory cytokines and chemokines as well 
as growth factors. The astrocyte response to molecular changes in their microenvironment shapes the 
recruitment and activation of peripheral immune cells, modulation of the BBB, and cell-cell interaction 
(not shown). ATP = adenosine triphosphate, BAFF = B-cell activating factor, BBB = blood-brain barrier, 
CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, DAMPs = damage-associated 
molecular pattern, IL = interleukin, IFN = interferon, PAMP = pathogen-associated molecular pattern, 
PRR = pattern recognition receptor, TNF = tumor necrosis factor.
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sclerosis, astrocytes have been shown to express CXCL12, a T cell chemoattractant, 
and B-cell activating factor (BAFF), a B cell chemoattractant [116, 117]. Like their 
influence on microglia and macrophages, cytokines released by reactive astrocytes 
can shift T cells to adopt either a more beneficial or detrimental phenotype. For 
example, reactive astrocytes during autoimmunity release pro-inflammatory 
cytokines, including TNF, IFN-γ, and IL-17, which may induce T cells to adopt a 
more pro-inflammatory state. However, astrocytes have also been shown to release 
IL-10 that shifts T cells towards the anti-inflammatory spectrum [23, 24, 32, 118, 
119]. Similarly, in a murine spinal cord injury model reactive astrocytes have been 
shown to release anti-inflammatory TGF-β [31]. Further studies examining the 
influences of reactive astrocytes on T cells are needed to better understand the 
long-term effects of astrogliosis on adaptive immune cells during CNS recovery 
after injury.
7. Reactive astrocytes as a pro-inflammatory regulator
Reactive astrocytes can release a variety of molecular signals that contribute 
to the inflammatory state of the CNS after injury or disease by directly activating 
immune defenses with the release of cytokines, chemokines, and other growth 
factors (Table 2). Recent advancements in astrocyte transcriptome analysis have 
begun to reveal the context specific production of pro-inflammatory molecules 
by astrocytes as well as molecular triggers that induce their production. Analysis 
of the astrocyte transcriptome after in vivo exposure to lipopolysaccharide (LPS) 
or infection significantly promoted the production of a pro-inflammatory, 
neurotoxic molecular profile [26, 52]. However, the astrocyte transcriptome 
shifts towards an anti-inflammatory, neuroprotective profile in an in vivo isch-
emia model [52]. Future studies should utilize single-cell sequencing techniques 
to transcriptionally define individual astrocyte responses during health and 
disease.
Despite the number of astrocyte transcriptome data available, few studies have 
attempted to elucidate mechanisms and signaling cascades that mediate astrocyte 
pro-inflammatory production. Recent studies have indicated NFκB and SOC3 as 
transcriptional regulators of pro-inflammatory astrocytes after a traumatic brain 
injury and during autoimmune inflammation [31, 32, 37]. In a model of autoim-
munity, genetic deletion of astrocyte derived NFκB results in increased expression 
of ECM components and pro-inflammatory cytokines [129]. Astrocytes have also 
been shown to release CCL2 and CXCL10 to recruit perivascular leukocytes dur-
ing autoimmune inflammation [124–126]. While the role of CCL2 and CXCL10 is 
diverse, evidence suggests that these molecules produced by astrocytes promote 
leukocyte migration in the CNS parenchyma [124]. In an autoimmune inflammation 
model, IL-17 inflammatory induction has been shown to be mediated by astrocyte 
Act1 signaling. Genetically deleting Act1/IL-17 signaling from astrocytes in an 
EAE model prevents the induction of pro-inflammatory cytokines [28]. Reactive 
astrocytes can also shift towards a more pro-inflammatory state by overexpressing 
pro-inflammatory cytokines. In spinal cord injury and autoimmune models, the 
overexpression of IL-6 in astrocytes leads to increased immune cell infiltration. 
The proinflammatory cytokine, IL-1β, produced by astrocytes, has also been shown 
to initiate a signaling cascade that releases vasoactive endothelial growth factor 
(VEGF), leading to increased BBB permeability and leukocyte leakage [127, 128]. In 
general, there is also evidence that astrocytes contribute to triggering inflammatory 
responses due to increases in neuronal activity in epilepsy, neuropathic pain, and 
stress [130].
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8. Reactive astrocytes as an anti-inflammatory regulator
Despite the growing body of work that suggests pro-inflammatory roles for 
astrocytes, there is an equal amount of evidence suggesting these cells limit 
inflammation. Recent loss-of-function experiments have also revealed essential 
anti-inflammatory roles of astrocytes after a variety of CNS injury and disease 
states (Table 2). These studies have also revealed specific molecular mechanisms 
that mediate these anti-inflammatory roles. The astrocyte TGF-β response seems 
to selectively affect astrocyte cytokine and chemokine production after ischemia 
in murine models. The genetic deletion of TGF-β signaling in astrocytes leads 
to diffused inflammation and enhances myeloid cell activation [43, 44]. After 
toxoplasmic encephalitis, the genetic loss of astrocyte TGF-β signaling can 
lead to the increase of infiltrating T cells. Notably, in both examples, astrocyte 
TGF-β signaling controls infiltration immune cell number but not necessarily 
Type Astrocyte 
molecule
Immune outcome References
Anti-inflammatory function
Cytokines IL-6 and IL-10 Activation of numerous anti-
inflammatory signaling pathways
[95, 120]
Growth factors TGF-β Activation of numerous anti-
inflammatory signaling pathways
[121, 122]
SHH Maintenance of BBB, increase of 
astrocyte proliferation
[36, 123]
Intracellular signaling 
molecules
STAT3 Suppression of multiple pro-
inflammatory signaling pathways
[37–39]
Receptors ERα and Gp130 Suppression of multiple pro-
inflammatory signaling pathways
[23, 25]
Pro-inflammatory function
Chemokines CCL2 and CCL5 Increase recruitment of leukocytes [95, 120, 122, 
124, 125]
CXCL1, CXCL10, 
and CXCL12
Increase recruitment of leukocytes [95, 120, 122, 
126]
Cytokines IL-6, IL-17, IL-1β, 
and TNF
Activation of numerous pro-
inflammatory signaling pathways
[95, 120–122]
Growth factors VEGF Increase of BBB permeability, 
increase of leukocyte infiltration
[127, 128]
Intracellular signaling 
molecules
NFκB and Soc3 Activation of numerous pro-
inflammatory signaling pathways
[31, 32, 37]
Act1 Activation of IL-17-mediated pro-
inflammatory signaling pathways
[28]
As immune-competent cells, astrocytes can detect injury signals and respond with the release of cytokine, chemokines, 
and growth factors as well initiating intracellular signaling pathways. Data suggests that the downstream effects of 
astrocyte activation is context- and time-dependent, and that both factors as well as other microenvironment stimuli 
can shift reactive astrocytes to either a more beneficial or detrimental phenotype.
Act = actin, CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, Gp = glycoprotein, 
IL = interleukin, IFN = interferon, NFκB = nuclear factor kappa B, EAE = experimental autoimmune 
encephalomyelitis, SHH = sonic hedgehog, Soc3 = suppressor of cytokine signaling 3, STAT3 = signaling 
transducer and activator of transcription 3, TGF = transforming growth factor β, TNF = tumor necrosis factor, 
VEGF = vascular endothelial growth factor.
Table 2. 
Pro- and anti-immune responses of astrocyte molecules.
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the immune response profile. Astrocyte signaling involving gp130, a receptor 
for IL-6, or estrogen receptor 1α has also been shown to be anti-inflammatory. In 
autoimmune and infection models, the genetic deletion of gp130 from astrocytes 
results in increased inflammatory cytokine production [24, 25]. Similar outcomes, 
such as increased myeloid infiltration and mortality, are observed in autoimmune 
models when estrogen receptor 1α is conditional deleted from astrocytes [23]. 
During autoimmunity, mice deficient in functional IFNγ signaling in astrocytes 
result in exacerbated disease and mortality due to enhanced leukocyte infiltration 
and an upregulation of inflammatory gene expression, including CCL1, CCL5, 
CXC10, and TNF [119]. These mice also had a reduction in anti-inflammatory 
cytokines, such as IL-10 and IL-27, when compared to mice with functional IFNγ 
in astrocytes [119].
9. Reactive astrocytes as a neuroprotector of the CNS
In addition to astrocyte regulation of the immune response, these glial cells can 
respond to CNS injury by altering neuronal function or survival. Neuronal insults 
result in the release of numerous signals, including increased glutamate production, 
ATP release and vascular damage. During numerous CNS disease states, including 
stroke, traumatic injury, epilepsy, neurodegeneration, and viral infection, injured 
and dying neurons release glutamate, which is harmful to neurons [131–134]. 
Astrocytes have been shown to take up excessive extracellular glutamate and 
dampen the neurotransmitter’s excitotoxicity on neurons, resulting in decreased 
neuronal death [135]. In vitro studies have also shown that glutamate signaling in 
astrocytes decrease their production of CCL5, a T cell chemoattractant, reducing 
overall neuroinflammation [136].
10. Reactive astrocytes as a neurotoxin of the CNS
Inflammation itself can unfortunately impair astrocyte uptake of glutamate, 
which leads to increased neuronal toxicity and a positive feedback of neuroin-
flammation [137]; for example, in an in vitro study TNF, released by microglia, 
signals to astrocyte to release glutamate, increasing excitotoxicity [138]. Neuronal 
injury and death also lead to the release of potassium and ATP. Both potassium 
and ATP can activate the inflammasome complex, which is an innate immune 
mechanism that when activated, resulting in the production of proinflammatory 
cytokines and increased inflammatory responses. The activation of the inflamma-
some complex, in this case, is through pannexin 1 channels, expressed by astro-
cytes [139, 140]. Pannexin 1 channels are opened by potassium and ATP, and once 
opened, activate the inflammasome complex, leading to the increased production 
of pro-inflammatory mediators, such as IL-1β, reactive oxygen and nitrogen 
species, and CCL2, a myeloid cell chemoattractant [139, 141–143]. ATP also can 
induce the release of glutamate from astrocytes, which can contribute to overall 
excitotoxicity [144]. During health, astrocytes release stored glycogen which 
is converted to lactate and transported to metabolically support neurons [145]. 
Neurons can resist excitotoxicity when astrocytes increase their glycogen uptake 
and lactate delivery [146]. Pro-inflammatory cytokines, including IL-1β as well 
as IFN-γ, TNF, and IL-6, negatively impacts this process by reducing glycogen 
storage and lactate transport in astrocytes that is necessary as an energy source of 
neurons [147, 148].
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11. Conclusions
Despite the recent advances in defining the role of astrocytes in regulating 
neuroinflammation, our understanding of these complex glial cells is only begin-
ning. A few studies have demonstrated astrocyte polarization after various CNS 
injuries [26, 52, 95]. In this model, “A1” reactive astrocytes are pro-inflammatory, 
neurotoxic while “A2” reactive astrocytes are anti-inflammatory, neuroprotective. 
Future research, however, is needed to determine whether, like the inflammatory 
microglia and macrophages, reactive astrocytes shift phenotypes along a spectrum 
of responses. The amount of new technology available to researchers will also make 
it possible to further dissect the complexity of astrocytes. Single-cell transcriptional 
profiling techniques, specifically, can be used as a tool to identify astrocyte subtypes 
as well as intracellular signaling networks. This method has already been utilized to 
reveal distinct astrocyte types with regionally restricted distribution in the healthy 
mouse brain [149]. A key goal, however, for researchers in the future will be to 
elucidate signaling networks that are relevant to CNS injury and disease and how 
immune pathways influence astrocyte reactivity.
While current research focuses primarily on astrocyte interactions with other 
CNS cell types, such as neurons, microglia, pathogens and infiltrating immune 
cells, future studies will need to examine how other biologic variables, including 
age and sex, influence astrocyte effects within the central and peripheral immune 
systems. Additionally, there is already some evidence that astrocyte immune regula-
tion is influenced by the gut microbiome [150], but the implications and effects of 
this process on health and disease are unknown.
In summary, astrocytes exhibit diverse and sometimes conflicting roles in the 
setting of neuroinflammatory diseases. These multipurpose glia cells not only sense 
and influence damaged neurons but appear to summate multiple signals to develop 
specific responses that modulate neuroinflammation. It is our hope that under-
standing how astrocytes receive and response to information as they perform these 
differential roles will lead to therapies that specifically target astrocytes during CNS 
injury and disease.
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